

ACR Convergence 2025

October 24–29, 2025
Chicago, United States



TOP ABSTRACTS

To help navigate the exciting content being presented at the American College of Rheumatology (ACR) Convergence 2025, the PsOPsA Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in psoriatic disease.

ACR 2025: Top abstracts in psoriasis and psoriatic arthritis

October 24–29, 2025

Oral presentations: Monday, October 27

#	Title	Presenter	Time (CDT)
0873 View	Sex differences in proteomic profiles and the impact of deucravacitinib treatment in patients with active psoriatic arthritis: A pooled phase 3 analysis	Lihi Eder	10:00–10:15
0874 View	Impact of deucravacitinib on disease activity in patients with psoriatic arthritis (PsA): Results from the pivotal phase 3 PsA studies	Atul Deodhar	10:15–10:30
0875 View	Efficacy and safety of icotrokinra, a novel targeted oral peptide (IL-23R-Inhibitor), in adolescents with moderate-to-severe plaque psoriasis: Subgroup analyses from a phase 3, randomized, double-blind, placebo-controlled study (ICONIC-LEAD)	Joseph Merola	10:30–10:45
0877 View	Therapeutic approach in patients with arthralgia at risk of progression to psoriatic arthritis	Rodrigo Garcia Salinas	11:00–11:15

Oral presentations: Wednesday, October 29

#	Title	Presenter	Time (CDT)
2689 View	Comparison of incidence of psoriatic arthritis in patients with psoriasis treated with interleukin-17 inhibitors vs interleukin-23 inhibitors, interleukin-12/23 inhibitors, and tumor necrosis factor inhibitors in real-world practice: A retrospective study	Laura C. Coates	12:00–12:15
LB20 View	Efficacy and safety of deucravacitinib up to Week 52: A multicenter, randomized, double-blind, placebo-controlled, phase 3 study in patients with active psoriatic arthritis who are naive to biologic disease-modifying antirheumatic drugs	Philip J. Mease	08:15–8:30

Posters			
#	Title	Presenter	Date and time (CDT)
0555 View	Phase 3 results from an innovative trial design of treating plaque psoriasis involving difficult-to-treat, high-impact sites with icotrokinra, a targeted oral peptide that selectively inhibits the IL-23–receptor	Joseph Merola	Sunday, October 26, 10:30–12:30
0567 View	Sonelokimab in biologic-experienced patients with active psoriatic arthritis: Results from a phase 2 trial (ARGO) and study design of a phase 3 trial (IZAR-2) in patients with inadequate response or intolerance to biologic TNFi, including a risankizumab reference arm	Atul Deodhar	Sunday, October 26, 10:30–12:30
0574 View	Bimekizumab 3-year efficacy in patients with psoriasis and risk factors for progression to psoriatic arthritis or screening positive for psoriatic arthritis: Long-term results from five phase 3/3b trials	Joseph Merola	Sunday, October 26, 10:30–12:30
0576 View	Factors impacting progression from oligoarticular to polyarticular PsA: Data from the FOREMOST study	Laura C. Coates	Sunday, October 26, 10:30–12:30
0590 View	Effect of deucravacitinib treatment on disease activity–associated plasma biomarkers in patients with active psoriatic arthritis: Results from 2 phase 3 studies	Vinod Chandran	Sunday, October 26, 10:30–12:30
1443 View	Long-term safety and efficacy of upadacitinib in patients with psoriatic arthritis: 5-year results from the phase 3 SELECT-PsA 1 study	Iain McInnes	Monday, October 27, 10:30–12:30
1447 View	Long-term impact of secukinumab on the prevention of psoriatic arthritis in patients with psoriasis: A 5-year pooled analysis of the ERASURE, FIXTURE and SCULPTURE studies	Laura C. Coates	Monday, October 27, 10:30–12:30
1453 View	Real-world comparative effectiveness of upadacitinib in psoriatic arthritis: Evaluation of switching to upadacitinib versus tumor necrosis factor inhibitors or interleukin-17 inhibitors after first-line tumor necrosis factor inhibitors	Philip J. Mease	Monday, October 27, 10:30–12:30
1456 View	Long-term safety of tildrakizumab through Week 208 in patients with psoriatic arthritis: Results from the phase 2b open-label extension study	Philip J. Mease	Monday, October 27, 10:30–12:30
1459 View	Fungal infections, including <i>Candida</i> , in patients with active psoriatic arthritis (PsA) treated with secukinumab: A pooled analysis of 9 phase 3 trials	Shikha Singla	Monday, October 27, 10:30–12:30
1463 View	Effective prevention of psoriatic arthritis with secukinumab: A 5-year observation from the SERENA study	Uta Kiltz	Monday, October 27, 10:30–12:30

Posters (continued)			
#	Title	Presenter	Date and time (CDT)
2366 View	Association between skin and joint symptom control and patient-reported pain and health status among patients with psoriatic arthritis in the CorEvitas psoriatic arthritis/spondyloarthritis registry initiating biologic or targeted synthetic disease-modifying antirheumatic drugs	Philip J. Mease	Tuesday, October 28, 10:30–12:30
2341 View	Bimekizumab treatment resulted in long-term sustained reductions in disease impact assessed by the psoriatic arthritis impact of disease (PsAID)-12 questionnaire in patients with active psoriatic arthritis: Up to 3-year results from two phase 3 studies	Ana-Maria Orbai	Tuesday, October 28, 10:30–12:30
2362 View	Long-term efficacy and safety of risankizumab for csDMARD-IR patients with active psoriatic arthritis: 244-week results from the KEEPSAKE 1 trial	Mauro Keiserman	Tuesday, October 28, 10:30–12:30
2365 View	Sustained efficacy up to 3 years with bimekizumab treatment across GRAPPA core domains in patients with psoriatic arthritis: Long-term results from two phase 3 trials	Philip J. Mease	Tuesday, October 28, 10:30–12:30
2368 View	Inhibition of structural damage progression with guselkumab, a selective IL-23i, in participants with active PsA: Results through Week 24 of the phase 3b, randomized, double-blind, placebo-controlled APEX study	Philip J. Mease	Tuesday, October 28, 10:30–12:30
LB06 View	AgAIN study: First head-to-head trial of secukinumab vs. ustekinumab in TNF α inhibitor-experienced psoriatic arthritis patients reveals better efficacy across multiple domains	Frank Behrens	Tuesday, October 28, 10:30–12:30
LB08 View	Efficacy and safety of izokibep, a novel IL-17A Inhibitor, in patients with active psoriatic arthritis: Week 52 results from a randomized, double-blind, placebo-controlled, multicenter, phase 2b/3 study	Philip J. Mease	Tuesday, October 28, 10:30–12:30



ACR 2025

Follow us on X to keep up to date
with the latest from the congress

@psoriasis_hub



PsOPsAHub

Brought to you by

